• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在 STAMPEDE 试验平台中，将二甲双胍重新用作前列腺癌的治疗药物。

Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.

机构信息

Department of Oncology/Haematology, Kantonsspital, St. Gallen, Switzerland.

MRC Clinical Trials Unit, University College London, London, UK.

出版信息

Eur Urol. 2016 Dec;70(6):906-908. doi: 10.1016/j.eururo.2016.07.015. Epub 2016 Jul 19.

DOI:10.1016/j.eururo.2016.07.015
PMID:27450106
Abstract

Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.

摘要

二甲双胍是一种安全、耐受良好、价格低廉的治疗方法，可与当前前列腺癌的标准治疗方法联合使用。它的使用可能减轻去势治疗的有害副作用，并发挥额外的抗癌作用。它将于 2016 年夏季纳入 STAMPEDE 试验平台。这将检验二甲双胍作为一种重新用于治疗初诊时患有高危局部晚期或转移性前列腺癌的男性的真正用途。

相似文献

1
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.在 STAMPEDE 试验平台中，将二甲双胍重新用作前列腺癌的治疗药物。
Eur Urol. 2016 Dec;70(6):906-908. doi: 10.1016/j.eururo.2016.07.015. Epub 2016 Jul 19.
2
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.一项前瞻性、随机的初步研究评估二甲双胍和生活方式干预对接受雄激素剥夺治疗的前列腺癌患者的影响。
BJU Int. 2012 May;109(10):1495-502. doi: 10.1111/j.1464-410X.2011.10555.x. Epub 2011 Sep 20.
3
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.非甾体类抗雄激素单药治疗与促黄体生成素释放激素激动剂或手术去势单药治疗晚期前列腺癌的比较。
Cochrane Database Syst Rev. 2014 Jun 30;2014(6):CD009266. doi: 10.1002/14651858.CD009266.pub2.
4
Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.回复：丹尼尔·E·斯普拉特、张驰、扎卡里·S·祖姆施泰格、裴欣、张志刚、迈克尔·J·泽莱夫斯基。二甲双胍与前列腺癌：去势抵抗性疾病发展及前列腺癌死亡率降低。《欧洲泌尿外科杂志》2013年；63卷：709 - 716页
Eur Urol. 2013 Aug;64(2):e28. doi: 10.1016/j.eururo.2013.04.014. Epub 2013 Apr 18.
5
Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.二甲双胍的使用与雄激素剥夺治疗的晚期前列腺癌患者的生存改善相关。
J Urol. 2018 Dec;200(6):1256-1263. doi: 10.1016/j.juro.2018.06.031. Epub 2018 Jun 22.
6
Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.回复莉亚·本西蒙、萨米·苏伊萨和洛朗·阿祖莱致编辑的信，主题为：丹尼尔·E·斯普拉特、张弛、扎卡里·S·祖姆施泰格、辛培、张志刚、迈克尔·J·泽莱夫斯基。二甲双胍与前列腺癌：去势抵抗性疾病的发展及前列腺癌死亡率降低。《欧洲泌尿外科杂志》2013年；63卷：709 - 716页
Eur Urol. 2013 Aug;64(2):e29-30. doi: 10.1016/j.eururo.2013.04.015. Epub 2013 Apr 19.
7
An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.一项关于二甲双胍作为伴随疗法用于接受雄激素剥夺治疗的前列腺癌患者的开放标签试点研究。
Urol Int. 2017;98(1):79-84. doi: 10.1159/000448691. Epub 2016 Sep 30.
8
Timing of androgen deprivation for prostate cancer: benefits versus side effects--a patient-physician dialogue.前列腺癌雄激素剥夺治疗的时机：益处与副作用——医患对话
Urology. 2002 Nov;60(5):735-7. doi: 10.1016/s0090-4295(02)01964-7.
9
Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.二甲双胍可能对接受前列腺癌外照射放疗的男性没有保护作用。
BJU Int. 2019 May;123 Suppl 5:36-42. doi: 10.1111/bju.14709. Epub 2019 Apr 23.
10
[Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].[转移性前列腺癌患者：一线激素治疗或化疗激素治疗的推荐意见]
Urologe A. 2017 Nov;56(11):1424-1429. doi: 10.1007/s00120-017-0517-y.

引用本文的文献

1
In silico exploration of anti-prostate cancer compounds from differential expressed genes.基于差异表达基因的抗前列腺癌化合物的计算机探索。
BMC Urol. 2024 Jul 3;24(1):138. doi: 10.1186/s12894-024-01521-9.
2
Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer.即将出现的新型治疗靶点：前列腺癌骨转移治疗临床试验分析
Cancers (Basel). 2024 Jan 31;16(3):627. doi: 10.3390/cancers16030627.
3
Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759.
用复合物 I 抑制剂二甲双胍和 IACS-010759 靶向癌症和免疫细胞代谢。
Mol Oncol. 2024 Jul;18(7):1719-1738. doi: 10.1002/1878-0261.13583. Epub 2024 Jan 12.
4
Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer.二甲双胍通过激活新型超级增强子的 PTGR1 转录程序逃避前列腺癌。
Signal Transduct Target Ther. 2023 Aug 16;8(1):303. doi: 10.1038/s41392-023-01516-2.
5
A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways.一种新型双胍衍生物IM176通过调节AMPK-mTOR和雄激素受体信号通路诱导前列腺癌细胞死亡。
Prostate Int. 2023 Jun;11(2):83-90. doi: 10.1016/j.prnil.2022.11.003. Epub 2022 Nov 18.
6
PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal.PASTE：阻断前列腺癌的脂表型作为代谢治疗：一个理论建议。
Curr Med Chem. 2024;31(22):3265-3285. doi: 10.2174/0929867330666230607104441.
7
AMPK activation protects against prostate cancer by inducing a catabolic cellular state.AMPK 激活通过诱导分解代谢细胞状态来预防前列腺癌。
Cell Rep. 2023 Apr 25;42(4):112396. doi: 10.1016/j.celrep.2023.112396. Epub 2023 Apr 15.
8
A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer.二甲双胍对转移性前列腺癌患者疗效的回顾性研究
Clin Med Insights Oncol. 2023 Feb 1;17:11795549231152073. doi: 10.1177/11795549231152073. eCollection 2023.
9
Targeting lipid metabolism in metastatic prostate cancer.靶向转移性前列腺癌中的脂质代谢
Ther Adv Med Oncol. 2023 Jan 30;15:17588359231152839. doi: 10.1177/17588359231152839. eCollection 2023.
10
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.前列腺癌综述：遗传学、诊断、治疗选择和替代方法。
Molecules. 2022 Sep 5;27(17):5730. doi: 10.3390/molecules27175730.